drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous genetically engineered T cells expressing a chimeric antigen receptor targeting BCMA (TNFRSF17) on plasma cells to induce T-cell activation, cytokine release, and cytotoxic killing in multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes BCMA (TNFRSF17) on malignant plasma cells. Antigen engagement activates CD3ΞΆ and costimulatory domains (e.g., 4-1BB or CD28), driving T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated killing of BCMA-positive multiple myeloma cells, with potential persistence for ongoing immunosurveillance.
drug_name
Anti-BCMA CAR T-cell therapy
nct_id_drug_ref
NCT05887167